{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:25:51Z","timestamp":1770837951862,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Kaneka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00467-021-05211-8","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T02:02:42Z","timestamp":1630116162000},"page":"585-592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Liposorber\u00ae LA-15 system for LDL apheresis in resistant nephrotic syndrome patients"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8902-9736","authenticated-orcid":false,"given":"Mohammad","family":"Al-mousily","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Nicoara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Selewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Twombley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"5211_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/PHMT.S100803","volume":"8","author":"N Nourbakhsh","year":"2017","unstructured":"Nourbakhsh N, Mak RH (2017) Steroid-resistant nephrotic syndrome: past and current perspectives. Pediatr Health Med Ther 8:29\u201337","journal-title":"Pediatr Health Med Ther"},{"key":"5211_CR2","doi-asserted-by":"crossref","unstructured":"(1982) Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr 101:514\u2013518","DOI":"10.1016\/S0022-3476(82)80692-6"},{"key":"5211_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1681\/ASN.V85769","volume":"8","author":"P Tarshish","year":"1997","unstructured":"Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769\u2013776","journal-title":"J Am Soc Nephrol"},{"key":"5211_CR4","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00467-009-1138-5","volume":"24","author":"D Mekahli","year":"2009","unstructured":"Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, Van Damme-Lombaerts R, Palcoux JB, Cachat F, Lavocat MP, Bourdat-Michel G, Nobili F, Cochat P (2009) Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 24:1525\u20131532","journal-title":"Pediatr Nephrol"},{"issue":"3 Suppl 1","key":"5211_CR5","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","volume":"73","author":"R Saran","year":"2019","unstructured":"Saran R, Robinson B, Abbott KC, Agodoa LYC et al (2019) US Renal Data System 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 73(3 Suppl 1):A7\u2013A8","journal-title":"Am J Kidney Dis"},{"key":"5211_CR6","unstructured":"Liposorber LA-15 system - FDA Humanitarian Device Exemption. Apheresis For Focal Glomeruloscleprosis In\nAdults and Pediatric Patients. HDE H120005. 3\/20\/2018"},{"key":"5211_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"2","author":"JF Moorhead","year":"1982","unstructured":"Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309\u20131311","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"5211_CR8","first-page":"38","volume":"17","author":"WF Keane","year":"1991","unstructured":"Keane WF, Kasiske BL, O\u2019Donnell MP, Kim Y (1991) The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 17(5 Suppl 1):38\u201342","journal-title":"Am J Kidney Dis"},{"key":"5211_CR9","first-page":"S41","volume":"31","author":"WF Keane","year":"1991","unstructured":"Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O\u2019Donnell MP (1991) Hyperlipidemia and progressive renal disease. Kidney Int Suppl 31:S41-48","journal-title":"Kidney Int Suppl"},{"key":"5211_CR10","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1053\/j.ajkd.2003.08.012","volume":"42","author":"M Hattori","year":"2003","unstructured":"Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121\u20131130","journal-title":"Am J Kidney Dis"},{"key":"5211_CR11","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s00467-019-04296-6","volume":"34","author":"L Shah","year":"2019","unstructured":"Shah L, Hooper DK, Okamura D, Wallace D, Moodalbail D, Gluck C, Koziell A, Zaritsky JJ (2019) LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients. Pediatr Nephrol 34:2343\u20132350","journal-title":"Pediatr Nephrol"},{"key":"5211_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00467-006-0426-6","volume":"22","author":"Y Kawasaki","year":"2007","unstructured":"Kawasaki Y, Suzuki S, Matsumoto A, Takano K, Suyama K, Hashimoto K, Suzuki J, Suzuki H, Hosoya M (2007) Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis. Pediatr Nephrol 22:889\u2013892","journal-title":"Pediatr Nephrol"},{"key":"5211_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00540-008-0726-z","volume":"23","author":"J Oto","year":"2009","unstructured":"Oto J, Suga K, Matsuura S, Kondo S, Ohnishi Y, Inui D, Imanaka H, Kagami S, Nishimura M (2009) Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis. J Anesth 23:284\u2013287","journal-title":"J Anesth"},{"key":"5211_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/BF00864397","volume":"7","author":"M Hattori","year":"1993","unstructured":"Hattori M, Ito K, Kawaguchi H, Tanaka T, Kubota R, Khono M (1993) Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7:196\u2013198","journal-title":"Pediatr Nephrol"},{"key":"5211_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10157-007-0003-8","volume":"12","author":"S Kobayashi","year":"2008","unstructured":"Kobayashi S (2008) Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 12:9\u201315","journal-title":"Clin Exp Nephrol"},{"key":"5211_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/jcp.2003.012989","volume":"57","author":"VG Athyros","year":"2004","unstructured":"Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728\u2013734","journal-title":"J Clin Pathol"},{"key":"5211_CR17","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1681\/ASN.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006\u20132016","journal-title":"J Am Soc Nephrol"},{"key":"5211_CR18","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1681\/ASN.2004080629","volume":"16","author":"B Bussolati","year":"2005","unstructured":"Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase\/AKT-signaling pathway. J Am Soc Nephrol 16:1936\u20131947","journal-title":"J Am Soc Nephrol"},{"key":"5211_CR19","doi-asserted-by":"publisher","unstructured":"Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L (2013) Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev (12):Cd005425. https:\/\/doi.org\/10.1002\/14651858.CD005425.pub2","DOI":"10.1002\/14651858.CD005425.pub2"},{"key":"5211_CR20","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(76)91736-0","volume":"1","author":"P-J Lupien","year":"1976","unstructured":"Lupien P-J, Moorjani S, Awad J (1976) A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1:1261\u20131265","journal-title":"Lancet"},{"key":"5211_CR21","first-page":"1153","volume":"30","author":"K Tojo","year":"1988","unstructured":"Tojo K, Sakai S, Miyahara T (1988) Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Nihon Jinzo Gakkai Shi 30:1153\u20131160","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"5211_CR22","first-page":"193","volume":"337","author":"K Tojo","year":"1990","unstructured":"Tojo K, Sakai S, Miyahara T (1990) Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Prog Clin Biol Res 337:193\u2013194","journal-title":"Prog Clin Biol Res"},{"key":"5211_CR23","first-page":"257","volume":"9","author":"E Muso","year":"1994","unstructured":"Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S (1994) Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 9:257\u2013264","journal-title":"Nephrol Dial Transplant"},{"key":"5211_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","volume":"19","author":"E Muso","year":"2015","unstructured":"Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Yuzawa Y, Takemura T, Sugiyama S, Nishizawa Y, Ogahara S, Yorioka N, Sakai S, Ogura Y, Yukawa S, Iino Y, Imai E, Matsuo S, Saito T (2015) Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol 19:379\u2013386","journal-title":"Clin Exp Nephrol"},{"key":"5211_CR25","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00467-018-4061-9","volume":"34","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V (2019) An update on LDL apheresis for nephrotic syndrome. Pediatr Nephrol 34:1655\u20131669","journal-title":"Pediatr Nephrol"},{"issue":"408","key":"5211_CR26","first-page":"415","volume":"89","author":"E Muso","year":"2001","unstructured":"Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y; Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group (2001) Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408-415","journal-title":"Nephron"},{"key":"5211_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.5414\/CNP65423","volume":"65","author":"T Kobayashi","year":"2006","unstructured":"Kobayashi T, Ando Y, Umino T, Miyata Y, Muto S, Hironaka M, Asano Y, Kusano E (2006) Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol 65:423\u2013426","journal-title":"Clin Nephrol"},{"key":"5211_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fped.2019.00454","volume":"7","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Sanchez-Kazi C, Quiroga A, Twombley KE, Mathias R, Lo M, Chakraborty R, Mahesh S, Steinke J, Bunchman T, Zaritsky J (2019) Dextran-sulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single-arm intervention study. Front Pediatr 7:454\u2013454","journal-title":"Front Pediatr"},{"key":"5211_CR29","unstructured":"Post approval study of Liposorber LA-15 system for the treatment of focal segmental glomerulosclerosis in children. clinicaltrials.gov. NCT02235857"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05211-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05211-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05211-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T15:26:11Z","timestamp":1647271571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05211-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5211"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05211-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"5 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Medical University of South Carolina Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Twombley receives funding from Kaneka for the FDA post-approval study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}